News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

Epigenomics announces commercial launch of Epi proColon(R) in the U.S.

DGAP-News: Epigenomics AG / Key word(s): Product Launch 2016-04-27 / 07:49 The issuer is solely responsible for the content of this announcement. Press release Epigenomics announces commercial launch of Epi proColon(R) in the U.S. Berlin (Germany) and Germantown, MD (U.S.A.), April 26, 2016 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer […]

Read more

Epigenomics AG: Epigenomics to present data on novel blood-based test for the detection of lung cancer at AACR Annual Meeting 2016

DGAP-News: Epigenomics AG / Key word(s): Conference/Scientific publication 2016-04-18 / 11:15 The issuer is solely responsible for the content of this announcement. Epigenomics to present data on novel blood-based test for the detection of lung cancer at AACR Annual Meeting 2016 Berlin (Germany) and Germantown, MD (U.S.A.), April 18, 2016 – Epigenomics AG (Frankfurt Prime […]

Read more

Epigenomics AG: Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test

DGAP-News: Epigenomics AG / Key word(s): Alliance/Miscellaneous 2016-03-30 / 09:10 The issuer is solely responsible for the content of this announcement. Epigenomics enters strategic license and development agreement with BioChain on novel, blood-based lung cancer test BioChain to acquire exclusive development and commercial license for China Initiation of clinical study planned in 2016 with the […]

Read more

Epigenomics AG Reports Results for the Financial Year Ended December 31, 2015 and Provides Outlook for 2016

DGAP-News: Epigenomics AG / Key word(s): Final Results/Forecast 2016-03-18 / 06:00 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG Reports Results for the Financial Year Ended December 31, 2015 and Provides Outlook for 2016 – Product revenue growth of 88% year-on-year driven by successful start of commercialization of […]

Read more

Epigenomics AG: Bondholders resolve on amendment of the terms and conditions of the 2013 Convertible Bonds

DGAP-News: Epigenomics AG / Key word(s): Bond 2015-12-18 / 17:23 The issuer is solely responsible for the content of this announcement. Press release Epigenomics AG: Bondholders resolve on amendment of the terms and conditions of the 2013 Convertible Bonds: – Extension of the Term until December 31, 2016 – Amendment of the Anti-Dilution Protection Berlin […]

Read more

Epigenomics AG Announces 2015 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights

DGAP-News: Epigenomics AG / Key word(s): 9-month figures 2015-11-18 / 07:30 Epigenomics AG Announces 2015 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights Berlin (Germany) and Germantown, MD (U.S.A.), November 18, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial […]

Read more